[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648970":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":23,"locations":23,"responsibleParty":41,"collaborators":23,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":23,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":23,"enrollmentInfo":51,"targetDuration":23,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":23,"overallStatus":60,"whyStopped":23,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":23},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Multimodal Ablation Combined with Perioperative Tislelizumab and Chemotherapy","EXPERIMENTAL","Patients in this single arm will receive a multimodal ablation procedure, followed by perioperative tislelizumab in combination with platinum-based doublet chemotherapy , and subsequently undergo radical surgical resection. Adjuvant tislelizumab will be continued after surgery as per protocol.",[13,14,15,16],"Device: Multimodal Ablation","Drug: Neoadjuvant therapy","Procedure: Surgery","Drug: Adjunctive therapy",[18,24,31,36],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DEVICE","Multimodal Ablation","CT-guided preoperative multimodal ablation performed with multimodal tumor therapy system.Target lung lesions are ablated within 2 weeks after subject enrollment.",[9],null,{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Neoadjuvant therapy","Neoadjuvant tislelizumab (200 mg, IV, Q3W) combined with chemotherapy will be administered within 2 weeks after ablation. For patients with squamous NSCLC, cisplatin or carboplatin combined with paclitaxel will be used; for patients with non-squamous NSCLC, cisplatin or carboplatin combined with pemetrexed will be used, for a total of 3-4 cycles of treatment.",[9],[30],"Tislelizumab",{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":23},"PROCEDURE","Surgery","Surgical resection will be performed within 4-6 weeks after the last neoadjuvant treatment. The pulmonary lesions (including the ablated lesions) will be radically resected via surgery.",[9],{"type":25,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Adjunctive therapy","Adjuvant therapy will be initiated within 2-8 weeks after surgery. Postoperative adjuvant therapy with tislelizumab (400 mg, Q6W) will be maintained for up to 1 year. Concomitant chemotherapy is allowed during this period based on guidelines\u002Fconsensus or multidisciplinary team (MDT) discussion.",[9],[30],{"type":42,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100648970","phase-2-multimodal-ablation-combined-with-perioperative-tislelizumab-and-chemotherapy-for-resectable-ii-iiib-nsclc-100648970",false,"NCT07729670","Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC","Inclusion Criteria:\n\n* Age \\>= 18 years, either gender;\n* Pathologically confirmed stage II-IIIB (N2) squamous or non-squamous non-small cell lung cancer (NSCLC) according to the 9th edition of the AJCC\u002FUICC NSCLC staging system;\n* Presence of lesions suitable for ablation therapy confirmed by imaging evaluation;\n* Evaluated as resectable with R0 resection before enrollment, and consent to undergo radical surgical resection;\n* ECOG performance status score of 0-1;\n* Eligible for platinum-based doublet chemotherapy;\n* Adequate cardiopulmonary function to meet the requirements of curative surgical resection;\n* Sufficient organ function confirmed by laboratory tests within 28 days before enrollment:\n\n  * Blood routine: WBC \\>= 3.0×10\\^9\u002FL; ANC \\>= 1.5×10\\^9\u002FL; PLT \\>= 100×10\\^9\u002FL; HGB \\>= 90 g\u002FL.\n  * Liver function: AST \\\u003C= 5.0×ULN; ALT \\\u003C= 5.0×ULN; TBIL \\\u003C= 1.5×ULN;\n  * Renal function: Cr \\\u003C= 1.5×ULN;\n  * For patients receiving cisplatin: creatinine clearance \\>= 60 mL\u002Fmin.\n  * For patients receiving carboplatin: creatinine clearance \\>= 45 mL\u002Fmin.\n  * Coagulation function: INR \\\u003C= 1.5×ULN (\\\u003C=3×ULN for patients on anticoagulants; anticoagulants must be discontinued for one week before ablation); APTT \\\u003C= 1.5×ULN;\n* Fully understand the study and voluntarily sign the informed consent form (ICF).\n\nExclusion Criteria:\n\n* Tumor is adjacent to the hilum, invades major blood vessels, or has contraindications for surgery;\n* History of interstitial lung disease, non-infectious pneumonia, or uncontrolled pulmonary diseases including pulmonary fibrosis and acute lung disease;\n* Previous allogeneic stem cell transplantation or organ transplantation;\n* Previous radiotherapy or chemotherapy;\n* Previous local treatment (e.g., radioactive seed implantation, ablation) for the target ablation lesion;\n* Previous treatment with immune checkpoint inhibitors, including but not limited to anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies;\n* Complicated with severe cardiac, pulmonary, hepatic, renal insufficiency, or coagulation disorders;\n* Clinically significant cardio-cerebrovascular diseases, including but not limited to acute myocardial infarction within 6 months before enrollment, heart failure of NYHA class III or IV, ventricular arrhythmia ≥ grade 2, any history of cerebrovascular accident;\n* Underwent any major surgical procedure requiring general anesthesia within 28 days before enrollment;\n* Previous severe immune system diseases or active infection;\n* Pregnant or lactating female;\n* Complicated with other malignancies (un cured within 5 years);\n* Confirmed positive EGFR or ALK driver genes by genetic testing;\n* Any condition requiring systemic therapy with corticosteroids (\\>10 mg prednisone per day or equivalent) or other immunosuppressive drugs before enrollment;\n* Severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral therapy, including tuberculosis;\n* Known history of HIV infection;\n* Untreated chronic hepatitis B patients, chronic hepatitis B virus (HBV) carriers with HBV DNA ≥ 500 IU\u002FmL, or active hepatitis C virus (HCV) patients; (Note: Inactive hepatitis B surface antigen carriers, treated and stable hepatitis B patients (HBV DNA \\\u003C 500 IU\u002FmL), and cured hepatitis C patients are eligible.);\n* Received live vaccine within 28 days before enrollment;\n* Simultaneously participating in another therapeutic clinical study;\n* Other conditions considered unsuitable for participation in this study by the investigator.","ALL","18 Years",{"count":52,"type":53},42,"ESTIMATED","INTERVENTIONAL",[56],"PHASE2","This is a prospective, open-label, single-center, single-arm phase II clinical trial evaluating the efficacy and safety of multimodal ablation in combination with perioperative tislelizumab and chemotherapy in patients with pathologically confirmed resectable stage II-IIIB (N2) non-small cell lung cancer (NSCLC).",[59],"NSCLC","NOT_YET_RECRUITING","2026-07-23",{"date":63,"type":64},"2026-07-27","ACTUAL",{"date":66,"type":53},"2026-06",{"date":68,"type":53},"2031-06",{"name":5,"class":6}]